Brain D, Tulleners R, Lee X, Cheng Q, Graves N, Pacella R Cost-effectiveness analysis of an innovative model of care for chronic wounds patients. PLoS One. 2019 Mar 6;14(3):e0212366. doi: 10.1371/journal.pone.0212366. eCollection 2019.
Cheng Q, Graves N, Pacella RE Economic Evaluations of Guideline-Based Care for Chronic Wounds: a Systematic Review. Appl Health Econ Health Policy. 2018 Oct;16(5):633-651. doi: 10.1007/s40258-018-0403-9.
Courvoisier DS, Righi L, Béné N, Rae AC, Chopard P Variation in pressure ulcer prevalence and prevention in nursing homes: A multicenter study. Appl Nurs Res. 2018 Aug;42:45-50. doi: 10.1016/j.apnr.2018.06.001. Epub 2018 Jun 5.
Dreyfus J, Gayle J, Trueman P, Delhougne G, Siddiqui A Assessment of Risk Factors Associated With Hospital-Acquired Pressure Injuries and Impact on Health Care Utilization and Cost Outcomes in US Hospitals. Am J Med Qual. 2018 Jul;33(4):348-358. doi: 10.
Kapp S, Miller C, Santamaria N The quality of life of people who have chronic wounds and who self-treat. J Clin Nurs. 2018 Jan;27(1-2):182-192. doi: 10.1111/jocn.13870. Epub 2017 Aug 9.
Meehan R Transitions From Acute Care to Long-Term Care: Evaluation of the Continued Access Model. J Appl Gerontol. 2019 Apr;38(4):510-529. doi: 10.1177/0733464817723565. Epub 2017 Aug 8.
Padula WV, Pronovost PJ Addressing the multisectoral impact of pressure injuries in the USA, UK and abroad. BMJ Qual Saf. 2018 Mar;27(3):171-173. doi: 10.1136/bmjqs-2017-007021. Epub 2017 Sep 19.
Pal A, Goswami D, Cuellar HE, Castro B, Kuang S, Martinez RV Early detection and monitoring of chronic wounds using low-cost, omniphobic paper-based smart bandages. Biosens Bioelectron. 2018 Oct 15;117:696-705. doi: 10.1016/j.bios.2018.06.060. Epub 2018
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
